Visceral Leishmaniasis Portfolio

By 2020, DNDi aims to deliver from its VL-specific portfolio:

  • Potentially a safe, effective, low-cost, and short-course oral combination treatment
  • A new treatment for PKDL that is shorter course and better tolerated than current options
  • Treatment options for HIV/VL co-infected patients
  • A new first-line treatment regimen for visceral leishmaniasis in Latin America

 

Cutaneous Leishmaniasis Portfolio

By 2020, DNDi aims to deliver from its CL-specific portfolio:

  • A safe, effective, and shorter-course treatment for cutaneous leishmaniasis

 

The current portfolio for both visceral and cutaneous leishmaniasis includes:

Research

Research

DNDI-5421 & DNDI-5610 Oxaboroles
Aminopyrazoles
Leish H2L
CGH VL Series 1
Translation

Translation

DNDI-0690 Nitromidazole
CpG-D35
New CL Combination Therapies
DNDI-6148 Oxaborole
Development

Development

New treatments for HIV/VL
New VL Treatments Latin America
New Treatments for PKDL
MF/PM Combination for Africa
Implementation

Implementation

SSG&PM
New VL Treatments – Asia

 

For more details on each project, see DNDi‘s Global Portfolio